183 research outputs found
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushingâs disease: 12-month, Phase III pasireotide study
Measuring salivary cortisol is a simple, convenient
and accurate technique with potential value in monitoring
patients with hypercortisolism. This analysis reports
changes in late-night salivary cortisol (LNSC) during a
12-month, multicentre, Phase III study of patients with
Cushingâs disease who were randomized to pasireotide 600
or 900 lg sc bid. LNSC assessment was an exploratory
objective based on a single, optional measurement at
midnight ± 1 h on the same day as one of the 24-h urinary
free cortisol (UFC) measurements. Of 162 enrolled
patients, baseline LNSC was measured in 93. Sixty-seven
patients had levels above the upper limit of normal (ULN);
median baseline levels were 19.7 and 20.7 nmol/L in the
groups subsequently randomized to 600 lg (n = 40) and
900 lg (n = 27), respectively. Median LNSC levels
decreased from baseline to month 12; median changes in
patients who had baseline LNSC [ULN in the 600 and
900 lg groups were -13.4 nmol/L (â52.6 %; n = 19) and
-11.8 nmol/L (â56.1 %; n = 14), respectively. LNSC
normalized at months 6 and 12 in 25/67 (37.3 %) and 13/67
(19.4 %) patients, respectively; 10/25 and 8/13 patients
also had normalized UFC, and 7/25 and 4/13 had partial
UFC control (UFC [ULN and C50 % decrease from
baseline). There was a moderate correlation (r = 0.55) on
the log scale between individual patient LNSC and UFC
values when all time points were pooled. Pasireotide
decreased LNSC levels during 12 months of treatment.
Salivary cortisol may be a simple, convenient biomarker
for assessing treatment response in patients with Cushingâs disease
Use of late-night salivary cortisol to monitor response to medical treatment in Cushingâs disease
Objective
Monitoring of patients with Cushingâs disease on cortisol-lowering drugs is usually performed with urinary free cortisol (UFC). Late-night salivary cortisol (LNSC) has an established role in screening for hypercortisolism and can help to detect the loss of cortisol circadian rhythm. Less evidence exists regarding the usefulness of LNSC in monitoring pharmacological response in Cushingâs disease.
Design
Exploratory analysis evaluating LNSC during a Phase III study of long-acting pasireotide in Cushingâs disease (clinicaltrials.gov: NCT01374906).
Methods
Mean LNSC (mLNSC) was calculated from two samples, collected on the same days as the first two of three 24-h urine samples (used to calculate mean UFC [mUFC]). Clinical signs of hypercortisolism were evaluated over time.
Results
At baseline, 137 patients had evaluable mLNSC measurements; 91.2% had mLNSC exceeding the upper limit of normal (ULN; 3.2 nmol/L). Of patients with evaluable assessments at month 12 (nâ=â92), 17.4% had both mLNSC â€ULN and mUFC â€ULN; 22.8% had mLNSC â€ULN, and 45.7% had mUFC â€ULN. There was high variability in LNSC (intra-patient coefficient of variation (CV): 49.4%) and UFC (intra-patient CV: 39.2%). mLNSC levels decreased over 12 months of treatment and paralleled changes in mUFC. Moderate correlation was seen between mLNSC and mUFC (Spearmanâs correlation: Ïâ=â0.50 [all time points pooled]). Greater improvements in systolic/diastolic blood pressure and weight were seen in patients with both mLNSC â€ULN and mUFC â€ULN.
Conclusion
mUFC and mLNSC are complementary measurements for monitoring treatment response in Cushingâs disease, with better clinical outcomes seen for patients in whom both mUFC and mLNSC are controlled
A 12-month phase 3 study of pasireotide in cushing's disease
BACKGROUND: Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS: In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the upper limit of the normal range to receive subcutaneous pasireotide at a dose of 600 ??g (82 patients) or 900 ??g (80 patients) twice daily. Patients with urinary free cortisol not exceeding 2 times the upper limit of the normal range and not exceeding the baseline level at month 3 continued to receive their randomly assigned dose; all others received an additional 300 ??g twice daily. The primary end point was a urinary free cortisol level at or below the upper limit of the normal range at month 6 without an increased dose. Open-label treatment continued through month 12. RESULTS: Twelve of the 82 patients in the 600-??g group and 21 of the 80 patients in the 900-??g group met the primary end point. The median urinary free cortisol level decreased by approximately 50% by month 2 and remained stable in both groups. A normal urinary free cortisol level was achieved more frequently in patients with baseline levels not exceeding 5 times the upper limit of the normal range than in patients with higher baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, and clinical signs and symptoms of Cushing's disease diminished. Pasireotide was associated with hyperglycemia-related adverse events in 118 of 162 patients; other adverse events were similar to those associated with other somatostatin analogues. Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatment initiation and then stabilized; treatment with a glucose-lowering medication was initiated in 74 of 162 patients. CONCLUSIONS: The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropin-secreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.) Copyright © 2012 Massachusetts Medical Society
High variability in baseline urinary free cortisol values in patients with Cushing's disease
Objective
Twenty-four-hour urinary free cortisol (UFC) sampling is commonly used to evaluate Cushing's syndrome. Because there are few data on UFC variability in patients with active Cushing's disease, we analysed baseline UFC in a large patient cohort with moderate-to-severe Cushing's disease and assessed whether variability correlates with hypercortisolism severity. These data will help clinicians establish the minimum number of UFC samples required to obtain reliable data.
Design
Observational study (enrolment phase of Phase III study).
Methods
Patients (n = 152) with persistent/recurrent or de novo Cushing's disease and mean UFC (mUFC) â„1·5ĂULN (normal: 30â145 nmol/24 h) were included. Mean UFC level was calculated from four 24-h urine samples collected over 2 weeks.
Results
Over 600 24-h UFC samples were analysed. The mUFC levels of samples 1 and 2 and samples 3 and 4 were 1000 nmol/24 h (SD 1872) and 940 nmol/24 h (SD 2148), respectively; intrapatient coefficient of variation (CV) was 38% for mUFC. The intrapatient CV using all four samples was 52% (95% CI: 48â56). The intrapatient CV was 51% (95% CI: 44â58) for samples 1 and 2, 49% (95% CI: 43â56) for samples 3 and 4 and 54% (95% CI: 49â59) for samples 1, 2 and 3. Variability in mUFC increased as UFC levels increased. There were no correlations between UFC and clinical features of hypercortisolism.
Conclusions
There is intrapatient variability of approximately 50% in 24-h UFC measurements, which is relevant to targets set to estimate any treatment effect. Analysing more than two 24-h collection periods in individual patients does not result in a relevant decrease in variability. Interestingly, UFC levels did not correlate with hypercortisolism severity
A prospective, multicentre study to investigate the efficacy,
Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68. Epub 2007 Apr 25.
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group.
SourceHospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City, Mexico. [email protected]
Abstract
OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of acromegaly.
DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48 weeks of the study period, received 12 doses of octreotide LAR 10-30 mg every 4 weeks, and constituted the population used for this analysis.
MEASUREMENTS AND RESULTS: A clinically relevant reduction (i.e. to 2.5 microg/l and 20%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period.
CONCLUSION: Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease
Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly : data from the PRIMARYS study
To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naĂŻve patients with acromegaly. Symptoms were assessed using Patient-assessed Acromegaly Symptom Questionnaire (PASQ) and health-related quality of life (HRQoL) using the AcroQoL questionnaire. Correlations between PASQ and AcroQoL scores, and between PASQ/AcroQoL and growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels were also evaluated (post hoc). Acromegaly symptoms and HRQoL significantly improved from week 12 to week 48, with modest correlations at week 48 between PASQ total score (R = -0.55, p 50 % of baseline standard deviation) in PASQ total score and >40 % achieved a MID in AcroQoL global score (post hoc). Changes in PASQ scores were similar in biochemically controlled (GH levels â€2.5 ÎŒg/L and normal IGF-1 levels) and uncontrolled groups, while changes in global and psychological AcroQoL scores were greater in the controlled group. There was no correlation between changes in PASQ or AcroQoL scores and changes in GH or IGF-1 levels. Primary treatment with lanreotide Autogel over 1 year was associated with rapid and sustained improvements in clinical signs and symptoms and HRQoL in patients with acromegaly. Improvements in HRQoL, but not symptoms, were greater in those achieving biochemical control (ClinicalTrials.gov: NCT00690898; EudraCT: 2007-000155-34). The online version of this article (doi:10.1007/s11102-015-0693-y) contains supplementary material, which is available to authorized users
Association of SSTR2 Polymorphisms and Glucose Homeostasis Phenotypes: The Insulin Resistance Atherosclerosis Family Study
A Transplantable Phosphorylation Probe for Direct Assessment of G Protein-Coupled Receptor Activation
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have primarily been characterized according to their binding profiles. However, their ability to activate individual somatostatin receptor subtypes (sst) has not been directly assessed so far. Here, we transplanted the carboxyl-terminal phosphorylation motif of the sst2 receptor to other somatostatin receptors and assessed receptor activation using a set of three phosphosite-specific antibodies. Our comparative analysis revealed unexpected efficacy profiles for pasireotide, octreotide and somatoprim. Pasireotide was able to activate sst3 and sst5 receptors but was only a partial agonist at the sst2 receptor. Octreotide exhibited potent agonistic properties at the sst2 receptor but produced very little sst5 receptor activation. Like octreotide, somatoprim was a full agonist at the sst2 receptor. Unlike octreotide, somatoprim was also a potent agonist at the sst5 receptor. Together, we propose the application of a phosphorylation probe for direct assessment of G protein-coupled receptor activation and demonstrate its utility in the pharmacological characterization of novel somatostatin analogs
Longâterm efficacy and safety of onceâmonthly pasireotide in Cushing's disease: A Phase III extension study
Objectives
Many patients with Cushing's disease (CD) require chronic pharmacotherapy to control their hypercortisolism. We evaluated the efficacy and safety of longâacting pasireotide during a longâterm extension study in patients with CD.
Design
Openâlabel extension to a 12âmonth Phase III study of longâacting pasireotide in CD (N = 150; NCT01374906).
Patients
Patients with mean urinary free cortisol (mUFC) †upper limit of normal (ULN) or receiving clinical benefit at core study end could continue longâacting pasireotide during the extension.
Results
Eightyâone of 150 (54.0%) enrolled patients entered the extension. Median overall exposure to pasireotide at study end was 23.9 months; 39/81 (48.1%) patients completed the extension (received â„ 12 monthsâ treatment during the extension and could transit to a separate pasireotide safety study). mUFC was â€ULN in 42/81 (51.9%), 13/81 (16.0%) and 43/81 (53.1%) patients at extension baseline, month (M) 36 and last assessment. Median mUFC remained within normal limits. Median lateânight salivary cortisol was 2.6 Ă ULN at core baseline and 1.3 Ă ULN at M36. Clinical improvements were sustained over time. Fortyâtwo (51.9%) patients discontinued during the extension: 25 (30.9%) before M24 and 17 (21.0%) after M24. Hyperglycaemiaârelated AEs occurred in 39.5% of patients. Mean fasting glucose (FPG) and glycated haemoglobin (HbA1c) were stable during the extension, with antidiabetic medication initiated/escalated in some patients. Sixtyâsix (81.5%) and 71 (88.9%) patients were classified as having diabetes (HbA1c â„ 6.5%, FPG â„ 7.0 mmol/L, antidiabetic medication use, or history of diabetes) at extension baseline and last assessment.
Conclusions
Longâacting pasireotide provided sustained biochemical and clinical improvements, with no new safety signals emerging, supporting its use as an effective longâterm therapy for CD
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
Pituitary adenomas are associated with a variety of clinical manifestations resulting from excessive hormone secretion and tumor mass effects, and require a multidisciplinary management approach. This article discusses the treatment modalities for the management of patients with a prolactinoma, Cushing's disease and acromegaly, and summarizes the options for medical therapy in these patients
- âŠ